Sanofi (NASDAQ:SNY) Holdings Cut by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. cut its stake in shares of Sanofi (NASDAQ:SNY) by 43.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 31,400 shares of the company’s stock after selling 24,100 shares during the quarter. Polar Asset Management Partners Inc.’s holdings in Sanofi were worth $1,514,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Arkadios Wealth Advisors increased its position in Sanofi by 19.0% in the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after buying an additional 751 shares during the period. Kentucky Trust Co bought a new position in shares of Sanofi during the fourth quarter worth about $436,000. Park Avenue Securities LLC increased its holdings in shares of Sanofi by 14.3% in the 4th quarter. Park Avenue Securities LLC now owns 68,982 shares of the company’s stock worth $3,327,000 after acquiring an additional 8,615 shares during the period. Van ECK Associates Corp lifted its position in Sanofi by 18.1% in the 4th quarter. Van ECK Associates Corp now owns 662,762 shares of the company’s stock valued at $31,965,000 after purchasing an additional 101,726 shares during the last quarter. Finally, Sound Income Strategies LLC boosted its stake in Sanofi by 156,520.9% during the 4th quarter. Sound Income Strategies LLC now owns 67,347 shares of the company’s stock valued at $3,248,000 after purchasing an additional 67,304 shares during the period. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Up 1.6%

SNY stock opened at $51.68 on Friday. The firm has a market cap of $130.56 billion, a PE ratio of 20.76, a P/E/G ratio of 1.01 and a beta of 0.55. Sanofi has a 12 month low of $45.80 and a 12 month high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The firm has a 50 day simple moving average of $53.36 and a 200 day simple moving average of $51.90.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.04. The company had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The company’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.78 EPS. Equities research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be given a $2.0369 dividend. This is a positive change from Sanofi’s previous annual dividend of $1.48. The ex-dividend date of this dividend is Friday, May 9th. This represents a dividend yield of 3.1%. Sanofi’s dividend payout ratio (DPR) is 57.14%.

Analyst Ratings Changes

Several brokerages have commented on SNY. The Goldman Sachs Group began coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a “neutral” rating and a $65.00 price target on the stock. Hsbc Global Res raised Sanofi to a “strong-buy” rating in a research note on Monday, April 28th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. BNP Paribas initiated coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.